Search

Search Results

• THERAPEUTIC OPTIONS FOR PATIENTS WHO ARE NOT ELIGIBLE FOR INTENSIVE CHEMOTHERAPY

  Elihu Estey

  e2013050

  2013-07-12

  https://doi.org/10.4084/mjhid.2013.050

  2213

  PDF: 763

  HTML: 1638

• TREATMENT OF ACUTE MYELOID LEUKEMIA WITH 20-30% BONE MARROW BLASTS

  Luca Maurillo, Francesco Buccisano, Maria Ilaria Del Principe, Chiara Sarlo, Luigi Di Caprio, Concetta Ditto, Federica Giannotti, Daniela Nasso, Eleonora Ceresoli, Massimiliano Postorino, Marco Refrigeri, Sergio Amadori, Adriano Venditti

  e2013032

  2013-06-03

  https://doi.org/10.4084/mjhid.2013.032

  2874

  PDF: 1036

  HTML: 5568

• A case of atypical prolonged hematologic toxicity with azacitidine in Chronic Myelomonocytic Leukemia (CMML), review of literature and a proposal of management

  Elena Elli, Caterina Cecchetti, Angelo Belotti, Lorenza Borin, Enrico Maria Pogliani

  e2012017

  2012-03-13

  https://doi.org/10.4084/mjhid.2012.017

  1259

  PDF: 665

  HTML: 778

• EFFICACY OF VENETOCLAX COMBINED WITH AZACITIDINE IN ELDERLY PATIENTS WITH RELAPSED ACUTE MYELOID LEUKEMIA

  Linjuan Xu

  e2025058

  2025-08-31

  https://doi.org/10.4084/MJHID.2025.058

  1522

  PDF: 806

  Suppl. Files: 339

  Html: 141

• TP53-MUTATED MYELODYSPLASIA AND ACUTE MYELOID LEUKEMIA TP53 in MDS and AML

  Ugo Testa, Dr. Germana Castelli, Dr. Elvira Pelosi

  e2023038

  2023-06-29

  https://doi.org/10.4084/MJHID.2023.038

  2214

  PDF: 1744

  HTML: 559

• NEW TREATMENTS FOR MYELODYSPLASTIC SYNDROMES

  Francesco D'Alò, Mariangela Greco, Marianna Criscuolo, Maria Teresa Voso

  e2010021

  2010-08-11

  https://doi.org/10.4084/mjhid.2010.021

  2022

  PDF: 1039

  HTML: 736

• TREATMENT OF LOW-BLAST COUNT AML USING HYPOMETHYLATING AGENTS

  Eleonora De Bellis, Luana Fianchi, Francesco Buccisano, Marianna Criscuolo, Luca Maurillo, Laura Cicconi, Mattia Brescini, Maria Ilaria Del Principe, Ambra Di Veroli, Adriano Venditti, Francesco Lo-Coco, Maria Teresa Voso

  e2017045

  2017-07-01

  https://doi.org/10.4084/mjhid.2017.045

  4424

  PDF: 1787

  HTML: 1112

• INFECTIONS IN MYELODYSPLASTIC SYNDROME IN RELATION TO STAGE AND THERAPY

  Giuseppe Leone, Livio Pagano

  e2018039

  2018-07-01

  https://doi.org/10.4084/mjhid.2018.039

  4326

  PDF: 1474

  HTML: 629

• AZACITIDINE IN CHRONIC MYELOMONOCYTIC LEUKEMIA: AN EFFECTIVE AND MANAGEABLE APPROACH.

  Pasquale Niscola

  e2014020

  2014-02-16

  https://doi.org/10.4084/mjhid.2014.020

  1908

  PDF: 911

  HTML: 2788

• 5-Azacytidine in chronic myelomonocytic leukemia: case report and review of literature

  Mariangela Greco, Marianna Criscuolo, Luana Fianchi, Livio Pagano, Maria Teresa Voso

  e2011011

  2011-03-14

  https://doi.org/10.4084/mjhid.2011.011

  1650

  PDF: 776

  HTML: 1124

• The venetoclax/azacitidine combination targets the disease clone in Acute Myeloid Leukemia, being effective and safe in a patient with COVID VEN/AZA effectively targets AML clones

  Antonio Cristiano, Raffaele Palmieri, Emiliano Fabiani, Tiziana Ottone, Mariadomenica Divona, Arianna Savi, Francesco Buccisano, Luca Maurillo, Corrado Tarella, William Arcese, Maria Teresa Voso

  e2022041

  2022-04-28

  https://doi.org/10.4084/MJHID.2022.041

  1308

  PDF: 786

  HTML: 335

• DE NOVO AND THERAPY-RELATED MYELODYSPLASTIC SYNDROMES: ANALOGIES AND DIFFERENCES DE NOVO AND THERAPY-RELATED MYELODYSPLASTIC SYNDROMES

  Prof. Giuseppe Leone, Emiliano Fabiani, Maria Teresa Voso

  e2022030

  2022-04-28

  https://doi.org/10.4084/MJHID.2022.030

  1432

  HTML: 545

  PDF: 854

• Complete Remission Obtained with Azacitidine in a Patient with Concomitant Therapy Related Myeloid Neoplasm and Pulmonary Mucormycosis

  Saveria Capria, Federico De Angelis, Giuseppe Gentile, Silvia Maria Trisolini, Simonetta Brocchieri, Martina Canichella, Patrizia Chiusolo, Alessandra Micozzi, Robin Foà, Giovanna Meloni

  e2013048

  2013-07-10

  https://doi.org/10.4084/mjhid.2013.048

  1595

  PDF: 699

  HTML: 1926

• Hemophagocytic lymphohistiocytosis secondary to refractory acute myeloid leukemia resolved after second line treatment with azacitidine plus venetoclax

  Claudio Fozza

  e2024011

  2024-01-01

  https://doi.org/10.4084/MJHID.2024.011

  1712

  PDF: 1392

  HTML: 189

• ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION IN THERAPY-RELATED MYELOID NEOPLASMS (t-MN) OF THE ADULT: MONOCENTRIC OBSERVATIONAL STUDY AND REVIEW OF THE LITERATURE.

  Elisabetta Metafuni, Patrizia Chiusolo, Luca Laurenti, Federica Sorà, Sabrina Giammarco, Andrea Bacigalupo, Giuseppe Leone, Simona Sica

  e2018005

  2018-01-01

  https://doi.org/10.4084/mjhid.2018.005

  4241

  PDF: 1107

  HTML: 1397

• Complex and Multifaceted Therapy-Related Myeloid Neoplasm Following Laryngeal Cancer Treated with Cisplatin and Radiotherapy

  Pasquale Niscola

  e2013030

  2013-04-16

  https://doi.org/10.4084/mjhid.2013.030

  1218

  PDF: 775

  HTML: 1508

  Figure 1: 200

  Figure 2: 202

• THE GROWING ROLE OF THE BH3 MIMETIC DRUG VENETOCLAX IN THE THERAPY OF ACUTE MYELOID LEUKEMIA

  Elvira Pelosi, Dr. Germana Castelli, Ugo Testa

  e2022080

  2022-10-29

  https://doi.org/10.4084/MJHID.2022.080

  1562

  PDF: 1190

  HTML: 387

• TREATMENT WITH LOW-DOSE CYTARABINE IN ELDERLY PATIENTS (AGE 70 YEARS OR OLDER) WITH ACUTE MYELOID LEUKEMIA: A SINGLE INSTITUTION EXPERIENCE

  Maël Heiblig, Mohamed Elhamri, Isabelle Tigaud, Adriana Plesa, Fiorenza Barraco, Hélène Labussière, Sophie Ducastelle, Mauricette Michallet, Franck Nicolini, Claudiu Plesa, Eric Wattel, Gilles Salles, Xavier Thomas

  e2016009

  2016-01-01

  https://doi.org/10.4084/mjhid.2016.009

  7553

  PDF: 1540

  HTML: 1657

• Azacytidine failure revisited: an appraisal based on real life data from the MDS registry of the Hellenic Myelodysplastic Syndrome Study Group (HMDS). Azacytidine failure revisited

  IOANNIS KOTSIANIDIS

  e2019045

  2019-06-25

  https://doi.org/10.4084/mjhid.2019.045

  1122

  PDF: 884

  HTML: 267

• Morphologic leukemia-free state after venetoclax-based therapy in acute myeloid leukemia is associated with high relapse despite preserved short-term survival

  Kenta Motegi

  e2026048

  2026-04-30

  https://doi.org/10.4084/MJHID.2026.048

  320

  PDF: 331

  HTML: 77

• THROMBOCYTOPENIA IN PATIENTS WITH MYELODYSPLASTIC SYNDROMES - STILL AN UNSOLVED PROBLEM

  May Basood, Howard S. Oster, Moshe Mittelman

  e2018046

  2018-07-01

  https://doi.org/10.4084/mjhid.2018.046

  3237

  PDF: 1415

  HTML: 597

• Leukemia cutis in a patient with acute myeloid leukemia undergoing Azacitidine-Venetoclax: case presentation and review of the literature

  Elisa Buzzatti, Cristina Mauro, Caterina Botti, Roberta Presicci, Giovangiacinto Paterno, Raffaele Palmieri, Carmelo Gurnari, Flavia Mallegni, Elisa Meddi, Federico Moretti, Lucia Cardillo, Valeria Mezzanotte, Kristian Taka, Lucrezia De Marchi, Luca Maurillo, Francesco Buccisano, Adriano Venditti, Maria Ilaria Del Principe

  e2025013

  2025-02-27

  https://doi.org/10.4084/MJHID.2025.013

  1027

  PDF: 1141

  HTML: 125

• ASSOCIATION BETWEEN LEUKEMIC EVOLUTION AND UNCOMMON CHROMOSOMAL ALTERATIONS IN PEDIATRIC MYELODYSPLASTIC SYNDROME

  Viviane Lamim Lovatel, Beatriz Ferreira da Silva , Eliane Ferreira Rodrigues , Maria Luiza Rocha da Rosa Borges , Rita de Cássia Barbosa Tavares, Ana Paula Silva Bueno, Elaine Sobral da Costa, Terezinha de Jesus Marques , Teresa de Souza Fernandez

  e2024003

  2024-01-01

  https://doi.org/10.4084/MJHID.2024.003

  1212

  PDF: 1404

  HTML: 138

• Concurrent diagnosis of acute myeloid leukemia and symptomatic COVID-19 infection: a case report successfully treated with Azacitidine-Venetoclax combination

  Daniela Taurino, Marco Frigeni, Anna Grassi, Gianluca Cavallaro, Silvia Salmoiraghi, Orietta Spinelli, Alessandro Rambaldi, Federico Lussana

  e2021057

  2021-08-28

  https://doi.org/10.4084/MJHID.2021.057

  1301

  PDF: 522

  HTML: 191

• HEMATOPOIETIC CELL TRANSPLANTATION FOR OLDER PATIENTS WITH MDS

  Mazyar Shadman, Joachim Deeg

  e2014056

  2014-09-01

  https://doi.org/10.4084/mjhid.2014.056

  2091

  PDF: 786

  HTML: 3174

• PHYSICIAN’S ATTITUDE TOWARDS TREATMENT OF OLDER PATIENTS AND THE CHOICE OF THERAPY

  Felicetto Ferrara

  e2013025

  2013-04-10

  https://doi.org/10.4084/mjhid.2013.025

  2404

  PDF: 812

  HTML: 1939

• Is there a better therapeutic time window from diagnosis to treatment elderly acute myeloid leukemia patients receiving hypomethylating agents?

  Salvatore Perrone

  e2024055

  2024-06-29

  https://doi.org/10.4084/MJHID.2024.055

  599

  PDF: 821

  HTML: 112

• THE CHALLENGE OF AML IN OLDER PATIENTS

  Alan K Burnett

  e2013038

  2013-06-03

  https://doi.org/10.4084/mjhid.2013.038

  2243

  PDF: 1001

  HTML: 2195

• Treating relapsed/refractory acute myeloid leukemia with chidamide, fludarabine, cytarabine and granulocyte-colony stimulating factor with subsequent bridging to myeloablative allogeneic hematopoietic stem cell transplantation Treating relapsed/refractory acute myeloid leukemia with chidamide, fludarabine, cytarabine and G-CSF

  Wen Yao, Xinchen Fang, Peng Jiang, Juan Tong, Liangquan Geng, Xiaoyu Zhu, Baolin Tang, Xiang Wan, Kaidi Song, Lei Zhang, Ping Qiang, Guangyu Sun, Yongsheng Han, Huilan Liu, Zimin Sun

  e2022025

  2022-02-27

  https://doi.org/10.4084/MJHID.2022.025

  1816

  PDF: 593

  HTML: 320

• LYON-UNIVERSITY HOSPITAL EXPERIENCE WITH GEMTUZUMAB OZOGAMICIN THERAPY IN ACUTE MYELOID LEUKEMIA: A ‘REAL-LIFE’ STUDY Gemtuzumab ozogamicin in AML

  Xavier Thomas, Marica Laurino, sandrine loron, marie-virginie larcher, gaëlle fossard, mohamed elhamri, alexandre deloire, marie balsat, fiorenza barraco, hélène labussière, sophie ducastelle, myriam renault, eric wattel, maël heiblig, gilles salles

  e2020020

  2020-04-27

  https://doi.org/10.4084/mjhid.2020.020

  1873

  PDF: 1189

  HTML: 289

• Outcome of Allogeneic Hematopoietic Stem Cell Transplantation in a Child with Myelodysplastic Neoplasm with Complex Karyotype and ETV6 Variant: Challenges in Treatment

  Elaiza Almeida Antônio de Kós , Viviane Lamim Lovatel , Rita de Cássia Barbosa Tavares , Gerson Moura Ferreira , Bernadete Evangelho Gomes, Ana Paula Silva Bueno, Elaine Sobral da Costa , Teresa de Souza Fernandez

  e2024040

  2024-04-30

  https://doi.org/10.4084/MJHID.2024.040

  881

  PDF: 986

  HTML: 99

• ROLE AND TIMING OF HEMATOPOIETIC CELL TRANSPLANTATION FOR MYELODYSPLASTIC SYNDROME

  Teresa L Field, Claudio Anasetti

  e2010019

  2010-07-19

  https://doi.org/10.4084/mjhid.2010.019

  1388

  PDF: 687

  HTML: 1210

• RARE CYTOGENETIC ABNORMALITIES IN MYELODYSPLASTIC SYNDROMES

  Julie Schanz, Friederike Braulke, Detlef Haase

  e2015034

  2015-04-23

  https://doi.org/10.4084/mjhid.2015.034

  3868

  PDF: 1700

  HTML: 11707

  Figures Haase: 221

• Hematogenous Disseminated Pulmonary Tuberculosis in an Elderly Patient with Acute Myeloid Leukemia: A Case Report

  Yu xi Ding, Xiao Dong Liu, wenqiang kong

  e2026010

  2026-01-01

  https://doi.org/10.4084/MJHID.2026.010

  729

  PDF: 552

  HTML: 260

• EBV IN HODGKIN LYMPHOMA

  Giuseppina Massini, Doerte Siemer, Stefan Hohaus

  e2009013

  https://doi.org/10.4084/mjhid.2009.013

  1689

  PDF: 616

  HTML: 14016

• THE ROLE OF SLC22A4 IN ACUTE MYELOID LEUKEMIA

  Yingying Li, Yang Li, Wenguo Cheng

  e2025073

  2025-10-31

  https://doi.org/10.4084/MJHID.2025.073

  530

  PDF: 262

  HTML: 104

• Should every patient with MDS get iron chelation – probably yes.

  Kanjaksha Ghosh, Emanuele Angelucci, Federica Pilo, Kinjalka Ghosh

  e2017055

  2017-09-01

  https://doi.org/10.4084/mjhid.2017.055

  2354

  PDF: 965

  HTML: 386

• Fusion Gene Landscape in a Case of Acute Myelocytic Leukemia with Myelocyte Morphology

  Zhan Su, Yan Li, Haidong Zhu, Yaqi Wang, Meiying Yang

  e2025004

  2024-12-31

  https://doi.org/10.4084/MJHID.2025.004

  1228

  PDF: 1033

  HTML: 214

• Dose-modified lenalidomide induces sustained hematological response in patients with intermediate to high risk myelodysplasia

  Alhossain A. Khalafallah, Bernadene Fernandopulle, Terry Brain

  e2010012

  2010-05-31

  https://doi.org/10.4084/mjhid.2010.012

  1083

  PDF: 706

  HTML: 359

• MICRORNA-181A-3P AS A DIAGNOSTIC AND PROGNOSTIC BIOMARKER FOR ACUTE MYELOID LEUKEMIA

  Xiaoling Ma

  e2020012

  2020-02-26

  https://doi.org/10.4084/mjhid.2020.012

  1733

  PDF: 1057

  HTML: 229

• Can Polycythemia Vera evolve from Acute Myeloid Leukemia? A Case Report Showing a Simultaneous Minor JAK2 V617F Mutated Clone, De novo polycythemia vera following AML remission

  Beatrice Borsellino, Arianna Savi, Maria Rosaria Pascale, Elisa Meddi, Antonio Cristiano, TIZIANA OTTONE, Maria Cristina Rapanotti, Mariadomenica Divona, SERENA TRAVAGLINI, Enrico Attardi, Elisa Buzzatti, Francesco Buccisano, Maria Teresa Voso

  e2022058

  2022-06-29

  https://doi.org/10.4084/MJHID.2022.058

  1719

  PDF: 801

  HTML: 277